Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed Against the Human Immunodeficiency Virus Type 1 Gp41 Membrane-proximal External Region Protect Against Mucosal Challenge by Simian-human Immunodeficiency Virus SHIVBa-L

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2009 Nov 13

PMID 19906907

Citations 217

Authors

Ann J Hessell

Eva G Rakasz

David M Tehrani

Michael Huber

Kimberly L Weisgrau

Gary Landucci

Donald N Forthal

Wayne C Koff

Pascal Poignard

David I Watkins

Dennis R Burton

Affiliations

Soon will be listed here.

Abstract

The membrane-proximal external region (MPER) of HIV-1, located at the C terminus of the gp41 ectodomain, is conserved and crucial for viral fusion. Three broadly neutralizing monoclonal antibodies (bnMAbs), 2F5, 4E10, and Z13e1, are directed against linear epitopes mapped to the MPER, making this conserved region an important potential vaccine target. However, no MPER antibodies have been definitively shown to provide protection against HIV challenge. Here, we show that both MAbs 2F5 and 4E10 can provide complete protection against mucosal simian-human immunodeficiency virus (SHIV) challenge in macaques. MAb 2F5 or 4E10 was administered intravenously at 50 mg/kg to groups of six male Indian rhesus macaques 1 day prior to and again 1 day following intrarectal challenge with SHIV(Ba-L). In both groups, five out of six animals showed complete protection and sterilizing immunity, while for one animal in each group a low level of viral replication following challenge could not be ruled out. The study confirms the protective potential of 2F5 and 4E10 and supports emphasis on HIV immunogen design based on the MPER region of gp41.

Citing Articles

Mechanisms of sterilizing immunity provided by an HIV-1 neutralizing antibody against mucosal infection.

Richel E, Cordsmeier A, Bauer L, Fraedrich K, Vestweber R, Roshani B PLoS Pathog. 2024; 20(12):e1012777.

PMID: 39724193 PMC: 11670951. DOI: 10.1371/journal.ppat.1012777.

The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention.

Thavarajah J, Honge B, Wejse C Viruses. 2024; 16(6).

PMID: 38932203 PMC: 11209272. DOI: 10.3390/v16060911.

Mucosal application of the broadly neutralizing antibody 10-1074 protects macaques from cell-associated SHIV vaginal exposure.

Suphaphiphat K, Desjardins D, Lorin V, Dimant N, Bouchemal K, Bossevot L Nat Commun. 2023; 14(1):6224.

PMID: 37803011 PMC: 10558491. DOI: 10.1038/s41467-023-41966-4.

Antiviral neutralizing antibodies: from in vitro to in vivo activity.

Burton D Nat Rev Immunol. 2023; 23(11):720-734.

PMID: 37069260 PMC: 10108814. DOI: 10.1038/s41577-023-00858-w.

Neutralization Sensitivity and Evolution of Virus in a Chronic HIV-1 Clade B Infected Patient with Neutralizing Activity against Membrane-Proximal External Region.

Tang W, Yuan Z, Wang Z, Ren L, Li D, Wang S Pathogens. 2023; 12(3).

PMID: 36986419 PMC: 10052815. DOI: 10.3390/pathogens12030497.

References

Mascola J, Lewis M, Stiegler G, Harris D, Vancott T, Hayes D . Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999; 73(5):4009-18. PMC: 104180. DOI: 10.1128/JVI.73.5.4009-4018.1999. View

Zhang Z, Fu T, Casimiro D, Davies M, Liang X, Schleif W . Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. J Virol. 2002; 76(24):12845-54. PMC: 136722. DOI: 10.1128/jvi.76.24.12845-12854.2002. View

Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C . Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med. 2005; 11(6):615-22. DOI: 10.1038/nm1244. View

Pal R, Wang S, Kalyanaraman V, Nair B, Whitney S, Keen T . Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J Med Primatol. 2005; 34(5-6):226-36. PMC: 2362402. DOI: 10.1111/j.1600-0684.2005.00120.x. View

Binley J, Wrin T, Korber B, Zwick M, Wang M, Chappey C . Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol. 2004; 78(23):13232-52. PMC: 524984. DOI: 10.1128/JVI.78.23.13232-13252.2004. View

Parren P, Marx P, Hessell A, Luckay A, Harouse J, Cheng-Mayer C . Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol. 2001; 75(17):8340-7. PMC: 115078. DOI: 10.1128/jvi.75.17.8340-8347.2001. View

Hessell A, Hangartner L, Hunter M, Havenith C, Beurskens F, Bakker J . Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007; 449(7158):101-4. DOI: 10.1038/nature06106. View

Yant L, Friedrich T, Johnson R, May G, Maness N, Enz A . The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol. 2006; 80(10):5074-7. PMC: 1472056. DOI: 10.1128/JVI.80.10.5074-5077.2006. View

Mehandru S, Vcelar B, Wrin T, Stiegler G, Joos B, Mohri H . Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol. 2007; 81(20):11016-31. PMC: 2045579. DOI: 10.1128/JVI.01340-07. View

10.

Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G . A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993; 67(11):6642-7. PMC: 238102. DOI: 10.1128/JVI.67.11.6642-6647.1993. View

11.

Kaizu M, Borchardt G, Glidden C, Fisk D, Loffredo J, Watkins D . Molecular typing of major histocompatibility complex class I alleles in the Indian rhesus macaque which restrict SIV CD8+ T cell epitopes. Immunogenetics. 2007; 59(9):693-703. DOI: 10.1007/s00251-007-0233-7. View

12.

Baba T, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S . Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med. 2000; 6(2):200-6. DOI: 10.1038/72309. View

13.

Richman D, Wrin T, Little S, Petropoulos C . Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003; 100(7):4144-9. PMC: 153062. DOI: 10.1073/pnas.0630530100. View

14.

Hansen S, Vieville C, Whizin N, Coyne-Johnson L, Siess D, Drummond D . Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med. 2009; 15(3):293-9. PMC: 2720091. DOI: 10.1038/nm.1935. View

15.

Poignard P, Sabbe R, Picchio G, Wang M, Gulizia R, Katinger H . Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity. 1999; 10(4):431-8. DOI: 10.1016/s1074-7613(00)80043-6. View

16.

Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F . A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 2002; 17(18):1757-65. DOI: 10.1089/08892220152741450. View

17.

Mehandru S, Wrin T, Galovich J, Stiegler G, Vcelar B, Hurley A . Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J Virol. 2004; 78(24):14039-42. PMC: 533925. DOI: 10.1128/JVI.78.24.14039-14042.2004. View

18.

Pal R, Venzon D, Letvin N, Santra S, Montefiori D, Miller N . ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol. 2001; 76(1):292-302. PMC: 135699. DOI: 10.1128/jvi.76.1.292-302.2002. View

19.

Manrique A, Rusert P, Joos B, Fischer M, Kuster H, Leemann C . In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol. 2007; 81(16):8793-808. PMC: 1951363. DOI: 10.1128/JVI.00598-07. View

20.

Sanhadji K, Grave L, Touraine J, Leissner P, Rouzioux C, Firouzi R . Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice. AIDS. 2001; 14(18):2813-22. DOI: 10.1097/00002030-200012220-00002. View